Volume 5, Issue 8.In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.Take our post-test to claim CME credits:Physician post-testNurse post-testTo read a companion newsletter click here.The post Using Real World Data to Individualize HCV Management appeared first on DKBmed Radio. See acast.com/privacy for privacy and opt-out information.